PRESS RELEASE published on 01/31/2024 at 17:03, 2 years 1 month ago EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023 Vita 34 AG publishes preliminary figures on the course of business in 2023, reporting Group revenue of EUR 76.8 million and preliminary EBITDA of EUR 4.0 million, which fell short of expectations due to extraordinary charges. The company plans to invest in cell and gene therapies and CDMO following the merger with PBKM EBITDA 2023 Vita 34 AG Preliminary Figures Cell And Gene Therapies
PRESS RELEASE published on 11/10/2023 at 14:57, 2 years 4 months ago EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
PRESS RELEASE published on 09/27/2023 at 19:21, 2 years 5 months ago EQS-Adhoc: Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor
PRESS RELEASE published on 08/31/2023 at 10:30, 2 years 6 months ago Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
PRESS RELEASE published on 05/31/2023 at 08:00, 2 years 9 months ago Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
PRESS RELEASE published on 05/12/2023 at 09:10, 2 years 10 months ago Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
PRESS RELEASE published on 04/30/2023 at 12:00, 2 years 10 months ago Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
PRESS RELEASE published on 04/25/2023 at 18:43, 2 years 11 months ago EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
PRESS RELEASE published on 04/06/2023 at 20:39, 2 years 11 months ago EQS-Adhoc: 2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
Published on 03/26/2026 at 21:00, 20 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 20 minutes ago Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 8 hours 20 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 20:48, 32 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 2 hours 11 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 3 hours 3 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 13 hours 50 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
